Live webinar

Accelerating drug development by early unwanted immunogenicity testing

Complex immune responses elicited upon treatment with biotherapeutic drugs are now revolutionizing the field of immuno-oncology. However, unwanted immune responses exerted by biologics can result in severe adverse effects. Immunogenicity testing at the early phase of drug development therefore can play a crucial role to avoid possible clinical consequences of anti-drug antibody (ADA) responses. Testing unwanted immune responses during drug development is becoming increasingly important for pharmaceutical industries and regulatory agencies like the FDA and EMEA.  

This webinar will cover:  

  • Causes and consequences of unwanted immunogenicity 
  • In vitro cellular assays to assess unwanted immunogenicity, including T cell activation/proliferation and MAPPS (MHC-associated peptide proteomics) assays  
  • Strategies to manage and reduce unwanted immune responses 

Presenter: Sofie Pattijn, CTO, ImmunXperts

Register for session 1: July 25, 2019Register for session  2: July 25, 2019
Berlin, Germany (GMT+02:00) – 10:00 AM CET
London, United Kingdom (GMT+01:00) –  9:00 AM GMT
Singapore, Singapore (GMT+08:00) – 4:00 PM  
Berlin, Germany GMT+02:00) – 7:00 PM CET 
New York, USA (GMT-04:00) – 1:00 PM GMT 
San Francisco, USA (GMT-07:00) – 10:00 AM GMT

Sofie Pattijn, Ph.D., CTO at ImmunXperts SA, a service provider for drug development processes